What's In Store For Cumberland Pharma (CPIX) In Q3 Earnings?

By Zacks Investment ResearchStock MarketsNov 04, 2019 11:24PM ET

www.investing.com/analysis/whats-in-store-for-cumberland-pharma-cpix-in-q3-earnings-200482369

What's In Store For Cumberland Pharma (CPIX) In Q3 Earnings?

By Zacks Investment Research | Nov 04, 2019 11:24PM ET

Saved. See Saved Items.

This article has already been saved in your Saved Items

AAPL

+1.73%

Add to/Remove from Watchlist

CPIX

-2.21%

Add to/Remove from Watchlist

FOLD

+3.26%

Add to/Remove from Watchlist

TBPH

+0.86%

Add to/Remove from Watchlist

EYEN

-1.74%

Add to/Remove from Watchlist

Investors’ focus will likely be on developments related to Cumberland Pharmaceuticals Inc.’s (NASDAQ:CPIX) pipeline candidates, RediTrex and Caldolor, when the company reports third-quarter 2019 results.

The company’s earnings beat the Zacks Consensus Estimate in all the last four quarters with the average positive surprise being 119.76%.

Shares of Cumberland Pharmaceuticals have decreased 7.7% so far this year compared with the industry‘s increase of 4.6%.

In the last reported quarter, Cumberland Pharmaceuticals delivered a positive earnings surprise of 42.86%.

Things to Watch For

Cumberland Pharmaceuticals is focused on developing and commercializing branded prescription drugs targeting hospital acute care, gastroenterology, and oncology supportive care.

The company’s revenues were solid in the second quarter led by strong growth of antibiotic Vibativ, which more than offset loss of sales for Vaprisol and Ethyol. We note that Vibativ was acquired from Theravance Biopharma (NASDAQ:TBPH) in October 2018. We expect Vibativ’s solid performance to have continued in the third quarter. Vaprisol has been supply issues for quite some time now.

Meanwhile, the company has several pipeline candidates, which are being evaluated in mid-stage studies targeting different indications including liver and autoimmune diseases among others. These ongoing studies are likely to have driven operating expenses higher in the soon-to-be reported quarter.

The company had submitted a new drug application in January 2019 seeking approval for RediTrex (methotrexate) injection as a treatment for active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as severe disabling psoriasis. A regulatory application for Caldolor injection to include new geriatric, shortened infusion, pediatric, and safety data in its label was submitted in the second quarter. Investors are likely to keep an eye on any regulatory updates regarding these abovementioned applications in the announcement.

Earnings Whispers

Our proven model does not conclusively predict an earnings beat for Cumberland Pharmaceuticalsin this reporting cycle. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as you will see below.

Earnings ESP: Cumberland Pharmaceuticals’ Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at 11 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: Although Cumberland Pharmaceuticals Zacks Rank #3 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult.

Cumberland Pharmaceuticals Inc. Price and Consensus

Cumberland Pharmaceuticals Inc. Price and Consensus

Cumberland Pharmaceuticals Inc. price-consensus-chart | Cumberland Pharmaceuticals Inc. Quote

Stocks That Warrant a Look

Here are some pharma stocks that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases.

Amicus Therapeutics (NASDAQ:FOLD) has an Earnings ESP of +3.98% and a Zacks Rank #2. The company is scheduled to release third-quarter results on Nov 11. You can see the complete list of today’s Zacks #1 Rank stocks here.

Eyenovia (NASDAQ:EYEN) has an Earnings ESP of +10.51% and a Zacks Rank #2. The company is scheduled to release third-quarter results on Nov 13.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>

Amicus Therapeutics, Inc. (FOLD): Free Stock Analysis Report

Theravance Biopharma, Inc. (TBPH): Free Stock Analysis Report

Cumberland Pharmaceuticals Inc. (CPIX): Free Stock Analysis Report

Eyenovia, Inc. (EYEN): Free Stock Analysis Report

Original post

Zacks Investment Research

Nvidia Concentration Risk: Should Retail Investors Be Worried? By Timothy Fries - Feb 28, 2025

The fortune of Nvidia (NASDAQ:NVDA) is closely tied to Big Tech hyperscalers. Although the AI/GPU designer didn’t name its largest clients in the latest 10-K filing on Wednesday,...

2 Boring Safe-Play Stocks to Protect Against Market Turmoil By Jesse Cohen - Feb 28, 2025

In a market fraught with uncertainty, investors often seek refuge in defensive-minded stocks that offer stability and resilience. Two such stalwarts, Johnson & Johnson and...

2 Stocks Riding the Dominance of America’s Natural Gas Exports By Jea Yu - Feb 28, 2025

The United States is the largest exporter of liquefied natural gas (LNG), having surpassed Australia and Qatar in 2023. The United States exports an estimated 12.5 billion cubic...

Add a Comment

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:

Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
Only English comments will be allowed.
Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I have read Investing.com's comments guidelines and agree to the terms described.

I Agree

Write your thoughts here

Are you sure you want to delete this chart?

Delete Cancel

Post

Post also to:

Replace the attached chart with a new chart ?

Replace Cancel

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.

<div id="comment">
				<div class="comment js-comment" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="">
    <div class="mainComment js-content">
       <div class="commentInnerWrapper">
        <a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody">
                					<span class="commentUsername">
                    	<a href="{userLink}" class="js-user-link js-user-name">{username}</a>
					</span>
                                <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
                <div class="commentDropDown js-commentDropDownWrapper " data-user-id="" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

<div class="js-option addRow follow">
            <div class="js-follow-post-button" data-reg_ep="follow comment">
                <span class="alertfollowIcon middle"></span>Follow this post            </div>
            <div class="js-unfollow-post-button displayNoneImp">
                <span class="alertUnfollowIcon middle"></span>Unfollow this post            </div>
        </div>

<div class="addRow js-option save"  data-reg_ep="save comment">
		<a href="javascript:void(0);" class="js-save-item-btn" data-item-type="comments" data-item-id="{commentID}">
			<i class="saveItemBigIcon middle"></i>
			Save		</a>
	</div>
	<div class="addRow saveItemsConfirmation noHover displayNone js-saveItemResult">
		
<div class="content js-saveItemSuccess displayNone">
	<span class="mediumGreenSuccessIcon"></span><span>Saved. See <a href="/members-admin/saved-items" target="_blank">Saved Items</a>.</span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
<div class="content js-saveItemAlreadySaved saveItemAlreadySaved displayNoneImp">
	<span>This comment has already been saved in your <a href="/members-admin/saved-items" target="_blank">Saved Items</a></span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
	</div>

<div class="addRow shareButtons js-sharePopup displayNone">
			<div class="js-shareComment"><span class="js-shareCommentSpan"></span></div>
		</div>
	</div>
</div>
                 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div>             </div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="commentBigChart js-comment-chart" onclick="openViewChartPopup('{commentID}')">
					<img src="https://d1-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

<div class="reportComment js-flag float_lang_base_2">
                            <a href="javascript:void(0);" id="commentFlag_{commentID}">
                                <span class="reportCommentIcon middle"></span><span class="inlineblock middle">Report</span>
                            </a>
                        </div>
                    				</div>
					</div>
	   </div>
	</div>
	</div>			</div>
			<div id="reply">
				
    <div class="commentReply js-comment js-comment-reply" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="">
		<div class="commentInnerWrapper"><a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody js-content">
            				<span class="commentUsername">
					<a href="{userLink}" class="commentUsername js-user-link js-user-name" onMouseOver="">{username}</a>
				</span>
                        <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
			 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div> 			<div class="commentDropDown js-commentDropDownWrapper " data-user-id="" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

</div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="replyBigChart displayNone js-comment-chart">
					<img src="https://d1-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
				<span id="commentSmallChart{commentID}" class="commentSmallChart pointer js-comment-chart" onclick="openViewChartPopup('{commentID}')">
                    <img src="https://d1-invdn-com.investing.com/comments_images/{commentImageSmall}" width="116" height="52" alt="{commentAlt}">
                    <span class="chartMagnifyOverlay displayNone"></span>
                    <span class="searchGlassIcon chartMagnify displayNone"></span>
                </span>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

Are you sure you want to delete this chart?

Delete Cancel

Post

Replace the attached chart with a new chart ?

Replace Cancel

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

I feel that this comment is:

Spam

Offensive

Thank You!

Your report has been sent to our moderators for review

Central Banks

Interest Rates

Next Meeting

FED

4.50%

Mar 19, 2025

ECB

2.90%

Mar 06, 2025

BOE

4.50%

Mar 20, 2025

SNB

0.50%

Mar 20, 2025

RBA

4.10%

Apr 01, 2025

BOC

3.00%

Mar 12, 2025

RBNZ

3.75%

Apr 09, 2025

BOJ

0.50%

Mar 19, 2025

CBR

21.00%

Mar 21, 2025

RBI

6.25%

Mar 10, 2025

PBOC

3.10%

BCB

13.25%

Mar 19, 2025

US 30	43,788.5	+548.4	+1.27%
US 500	5,949.1	+87.4	+1.49%
Dow Jones	43,839.99	+600.49	+1.39%
S&P 500	5,950.50	+88.80	+1.51%
Nasdaq	18,847.28	+302.86	+1.63%
S&P 500 VIX	19.63	-1.50	-7.10%
Dollar Index	107.490	+0.314	+0.29%

Crude Oil WTI	70.04	-0.31	-0.44%
Brent Oil	73.10	-0.47	-0.64%
Natural Gas	3.831	-0.103	-2.62%
Gold	2,868.19	-27.71	-0.96%
Silver	31.433	-0.368	-1.16%
Copper	4.5613	-0.0572	-1.24%
US Soybeans	1,011.50	-11.25	-1.10%

U.S. 10Y	4.213	-0.074	-1.73%
U.S. 30Y	4.494	-0.060	-1.32%
U.S. 5Y	4.017	-0.088	-2.14%
U.S. 3M	4.305	-0.006	-0.14%
US 10Y T-Note	111.13	+0.52	+0.47%
Euro Bund	133.29	+0.40	+0.30%
10-2 Yield Spread	17.88	-1.73	-8.82%

Apple	241.84	+4.10	+1.73%
Alphabet A	170.28	+1.75	+1.04%
Tesla	292.98	+11.10	+3.94%
Amazon.com	212.28	+3.23	+1.55%
Netflix	980.56	+17.49	+1.82%
Meta Platforms	668.20	+9.96	+1.51%
Bank of America	46.10	+1.98	+4.49%

What's In Store For Cumberland Pharma (CPIX) In Q3 Earnings?

Related Articles